142 related articles for article (PubMed ID: 28389440)
1. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS).
Snowden JA; O'Connell S; Hawkins J; Dalley C; Jack A; Mannari D; McNamara C; Scott M; Shenton G; Soilleux E; Macbeth F;
J Clin Pathol; 2017 Jun; 70(6):461-468. PubMed ID: 28389440
[TBL] [Abstract][Full Text] [Related]
2. Implementation of the updated NICE haematological cancers (NG47) improving outcomes guidelines across Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS) in England: a UK NEQAS LI survey.
Cartwright A; Snowden JA; Whitehouse H; Scott S; Whitby L
J Clin Pathol; 2023 Sep; 76(9):618-623. PubMed ID: 35508367
[TBL] [Abstract][Full Text] [Related]
3. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model.
Dalley C; Basarir H; Wright JG; Fernando M; Pearson D; Ward SE; Thokula P; Krishnankutty A; Wilson G; Dalton A; Talley P; Barnett D; Hughes D; Porter NR; Reilly JT; Snowden JA
J Clin Pathol; 2015 Apr; 68(4):292-300. PubMed ID: 25631214
[TBL] [Abstract][Full Text] [Related]
4. Haematological cancers: improving outcomes. A summary of updated NICE service guidance in relation to Specialist Integrated Haematological Malignancy Diagnostic Services (SIHMDS).
Cuthbert RJG
J Clin Pathol; 2017 Jun; 70(6):469. PubMed ID: 28389439
[No Abstract] [Full Text] [Related]
5. Haematological malignancies: the rationale for integrated haematopathology services, key elements of organization and wider contribution to patient care.
Ireland R
Histopathology; 2011 Jan; 58(1):145-54. PubMed ID: 21261689
[TBL] [Abstract][Full Text] [Related]
6. Organisation of neoplastic haematopathology services: a UK perspective.
Jack A
Pathology; 2005 Dec; 37(6):479-92. PubMed ID: 16373228
[TBL] [Abstract][Full Text] [Related]
7. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network.
Smith A; Howell D; Patmore R; Jack A; Roman E
Br J Cancer; 2011 Nov; 105(11):1684-92. PubMed ID: 22045184
[TBL] [Abstract][Full Text] [Related]
8. Improving outcomes: update on progress.
Hollis R; Hooker L
Paediatr Nurs; 2009 May; 21(4):14-8. PubMed ID: 19505058
[TBL] [Abstract][Full Text] [Related]
9. What determines referral of UK patients with haematological malignancies to palliative care services? An exploratory study using hospital records.
Ansell P; Howell D; Garry A; Kite S; Munro J; Roman E; Howard M
Palliat Med; 2007 Sep; 21(6):487-92. PubMed ID: 17846088
[TBL] [Abstract][Full Text] [Related]
10. How many patients with haematological malignancy need the facilities offered by a district general hospital?
Low J; Smith A; George S; Roderick P; Davis C
J Public Health Med; 2002 Sep; 24(3):196-9. PubMed ID: 12831089
[TBL] [Abstract][Full Text] [Related]
11. The development of integrated haematopathology laboratories: a new approach to the diagnosis of leukaemia and lymphoma.
Richards SJ; Jack AS
Clin Lab Haematol; 2003 Dec; 25(6):337-42. PubMed ID: 14641135
[TBL] [Abstract][Full Text] [Related]
12. Translating biomedical science into clinical practice: Molecular diagnostics and the determination of malignancy.
Cox H; Webster A
Health (London); 2013 Jul; 17(4):391-406. PubMed ID: 23074299
[TBL] [Abstract][Full Text] [Related]
13. Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006-17.
Price S; Spencer A; Zhang X; Ball S; Lyratzopoulos G; Mujica-Mota R; Stapley S; Ukoumunne OC; Hamilton W
Cancer Epidemiol; 2020 Dec; 69():101805. PubMed ID: 32919226
[TBL] [Abstract][Full Text] [Related]
14. Incidence of haematological malignancies, Eastern Cape Province; South Africa, 2004-2013.
Oelofse D; Truter I
Cancer Epidemiol; 2018 Apr; 53():166-171. PubMed ID: 29462765
[TBL] [Abstract][Full Text] [Related]
15. Facilities for the treatment of adults with haematological malignancies--'Levels of Care': BCSH Haemato-Oncology Task Force 2009.
Matthey F; Parker A; Rule SA; Wimperis JZ; Ardeshna KM; Bird JM; Cullis J; Lyttelton MP; McMillan A; Jackson GH
Hematology; 2010 Apr; 15(2):63-9. PubMed ID: 20423565
[No Abstract] [Full Text] [Related]
16. Review of the NICE guidelines for multiple myeloma.
Pratt G; Morris TC
Int J Lab Hematol; 2017 Feb; 39(1):3-13. PubMed ID: 27997752
[TBL] [Abstract][Full Text] [Related]
17. [New horizons in evidence-based haematological oncology: outcome and importance of the scientific activities of the Cochrane Haematologicial Malignancies Group (CHMG)].
Kober T; Enger A
Z Arztl Fortbild Qualitatssich; 2006; 100(3):167-73. PubMed ID: 16768081
[TBL] [Abstract][Full Text] [Related]
18. A systematic review that evaluates one-stop neck lump clinics.
Cozens NJ
Clin Otolaryngol; 2009 Feb; 34(1):6-11. PubMed ID: 19260879
[TBL] [Abstract][Full Text] [Related]
19. Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN).
Li J; Smith A; Crouch S; Oliver S; Roman E
Cancer Causes Control; 2016 Aug; 27(8):1019-26. PubMed ID: 27351920
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer: risk factors, treatment and management.
Rooth C
Br J Nurs; 2013 Sep 12-25; 22(17):S23-30. PubMed ID: 24067270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
